Substance · official US FDA label
Erythromycine (erythromycin)
34 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for erythromycin, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for erythromycin, effective August 28, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for erythromycin
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given: a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.
Side effects
ADVERSE REACTIONS The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- Dermery 2% 0,02, solution dermique
- Erinocin 125mg par 5ml, poudre pour suspension orale
- Erinocin 250mg par 5ml, poudre pour suspension orale
- ERY 500 mg, comprimé
- Ery Enfants 250 mg, granulés
- ERY ENFANTS 250 mg, granulés en sachet
- Ery Enfants 500 mg, comprimé
- Ery Nourrissons 125 mg, granulés
- ERY NOURRISSONS 125 mg, granulés en sachet
- ERYFLUID, lotion
- ERYSHAL 500 500 mg, comprimé
- ERYTHROCINE 1 g, poudre pour solution à diluer pour perfusion
- ERYTHROCINE 500 mg, poudre pour solution à diluer pour perfusion
- ERYTHROGEL 4 %, gel pour application cutanée
- Erythromycine 0,5%, Pommade
- Erythromycine 125 mg/5 ml, suspension buvable
- Erythromycine 250 mg/5 ml, suspension buvable
- Erythromycine 250mg, comprimé
- Erythromycine 500 500 mg, comprimé
- Erythromycine 500 mg, comprimé
- ERYTHROMYCINE BAILLEUL 4 %, solution pour application cutanée
- ERYTHROMYCINE PANPHARMA 1 g, poudre pour solution à diluer pour perfusion
- ERYTHROMYCINE PANPHARMA 500 mg, poudre pour solution à diluer pour perfusion
- Erythromycine Stérage 250 mg, comprimé
- Erythromycine Stérage 500 mg, comprimé
- ERYTHRON 125 125 mg/5 ml, suspension
- Erythron 125 mg par 5 ml, suspension
- ERYTHRON 250 250 mg/5 ml, suspension
- Erythron 250 mg par 5 ml, suspension orale
- Erythron 250 mg, comprimé enrobé
- Erytron 125 125 mg, poudre pour suspension orale
- Erytron 250 250 mg, poudre pour suspension orale
- Erytron 500 mg, comprimé enrobé
- ERYLIK, gel pour application cutanée (in French)
Combined with other substances
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.